Enzyme replacement therapy in Fabry disease: Towards a better understanding of the implications of antibody formation and dose

Molecular Genetics and Metabolism

Volumn 95, Issue 4, 2008, Pages 239-240

  Hollak, C E M ^a   Vedder, A C ^a   Winchester, B ^b   Aerts, J M F G ^a   Breunig, F ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA;

AMINO ACID COMPOSITION; ANTIBODY PRODUCTION; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG MEGADOSE; ENZYME REPLACEMENT; FABRY DISEASE; FIBROBLAST; GLYCOSYLATION; HUMAN; LETTER; PRIORITY JOURNAL;

ANTIBODY FORMATION; BIOLOGICAL THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FABRY DISEASE; FEMALE; GALACTOSIDASES; HUMANS; MALE;

EID: 55949106935     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.08.006     Document Type: Letter

References (23)

1. Mehta A., Beck M., Kampmann C., Frustaci A., Germain D.P., Pastores G.M., and Sunder-Plassmann G. Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta. Mol. Genet. Metab. 95 (2008) 114-115
2. Vedder A.C., Breunig F., Donker-Koopman W.E., Mills K., Young E., Winchester B., Ten Berge I.J., Groener J.E., Aerts J.M., Wanner C., and Hollak C.E. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol. Genet. Metab. 94 (2008) 319-325
3. Linthorst G.E., Hollak C.E.M., Donker-Koopman W.E., Strijland A., and Aerts J.M. Enzyme therapy for Fabry disease: neutralizing antibodies towards agalsidase alpha and beta. Kidney Int. 66 (2004) 1589-1595
4. Whitfield P.D., Calvin J., Hogg S., O'Driscoll E., Halsall D., Burling K., Maguire G., Wright N., Cox T.M., Meikle P.J., and Deegan P.B. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 28 (2005) 21-33
5. Ohashi T., Sakuma M., Kitagawa T., Suzuki K., Ishige N., and Eto Y. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol. Genet. Metab. 92 (2007) 271-273
6. Schiffmann R., Ries M., Timmons M., Flaherty J.T., and Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transpl. 21 (2006) 345-354
7. Clarke J.T., West M.L., Bultas J., and Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet. Med. 9 (2007) 504-509
8. Lee K., Jin X., Zhang K., Copertino L., Andrews L., Baker-Malcolm J., Geagan L., Qiu H., Seiger K., Barngrover D., McPherson J.M., and Edmunds T. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiol. 13 (2003) 305-313
9. Sakuraba H., Murata-Ohsawa M., Kawashima I., Tajima Y., Kotani M., Ohshima T., Chiba Y., Takashiba M., Jigami Y., Fukushige T., Kanzaki T., and Itoh K. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J. Hum. Genet. 51 (2006) 180-188
10. Blom D., Speijer D., Linthorst G.E., Donker-Koopman W.G., Strijland A., and Aerts J.M. Recombinant enzyme therapy for Fabry disease. Absence of editing of human ‡-Galactosidase A mRNA. Am. J. Hum. Gen. 72 (2003) 23-31
11. Ledger V., Mills P., Mills K., Young E., and Winchester B. Comparison of the natural substrate specificity and glycosylation of the two commercial preparations of alpha-galactosidase A. Acta Paediatr. Suppl. (2007) 99
12. Vedder A.C., Linthorst G.E., Houge G., Groener J.E., Ormel E.E., Bouma B.J., Aerts J.M., Hirth A., and Hollak C.E. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE. 2 (2007) e598
13. Hughes D.A., Elliott P.M., Shah J., Zuckerman J., Coghlan G., Brookes J., and Mehta A.B. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 94 (2008) 153-158
14. Spinelli L., Pisani A., Sabbatini M., Petretta M., Andreucci M.V., Procaccini D., Lo Surdo N., Federico S., and Cianciaruso B. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin. Genet. 66 (2004) 158-165
15. Weidemann F., Breunig F., Beer M., Sandstede J., Turschner O., Voelker W., Ertl G., Knoll A., Wanner C., and Strotmann J.M. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108 (2003) 1299-1301
16. Levy D., Savage D.D., Garrison R.J., Anderson K.M., Kannel W.B., and Castelli W.P. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am. J. Cardiol. 59 (1987) 956-960
17. Breunig F., Weidemann F., Strotmann J., Knoll A., and Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 69 (2006) 1216-1221
18. Koskenvuo J.W., Hartiala J.J., Nuutila P., Kalliokoski R., Viikari J.S., Engblom E., Penttinen M., Knuuti J., Mononen I., and Kantola I.M. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J. Inherit. Metab. Dis. 31 (2008) 432-441
19. Moon J.C., Sheppard M., Reed E., Lee P., Elliott P.M., and Pennell D.J. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J. Cardiovasc. Magn. Reson. 8 (2006) 479-482
20. Moon J.C., Sachdev B., Elkington A.G., McKenna W.J., Mehta A., Pennell D.J., Leed P.J., and Elliott P.M. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur. Heart J. 24 (2003) 2151-2155
21. Beer M., Weidemann F., Breunig F., Knoll A., Koeppe S., Machann W., Hahn D., Wanner C., Strotmann J., and Sandstede J. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am. J. Cardiol. 97 (2006) 1515-1518
22. Beck M., Ricci R., Widmer U., Dehout F., de Lorenzo A.G., Kampmann C., Linhart A., Sunder-Plassmann G., Houge G., Ramaswami U., Gal A., and Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur. J. Clin. Invest. 34 (2004) 838-844
23. Ohashi T., Iizuka S., Ida H., and Eto Y. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol. Genet. Metab. 94 (2008) 313-318